Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Nathalie CoolenPierre-Régis Burgel

Abstract

Azithromycin reduces exacerbations in cystic fibrosis (CF) patients. Our aim was to investigate its association with nontuberculous mycobacteria isolation and macrolide susceptibility. From 2006 to 2010, all adult CF subjects at Cochin Hospital (Paris, France) harboring at least one positive NTM isolate were identified (Cases). In a nested case-control study, each Case was individually matched for age and gender with up to 4 CF adults with no NTM isolate (Controls). Clinical data at the time of first NTM isolate (index date) in Cases were compared with those of Controls using multivariate conditional regression analysis. CF subjects with positive NTM isolates (Cases, n=41) were matched to 155 Controls. Among Cases, 48.7% had isolates from Mycobacterium avium complex and 58.5% from Mycobacterium abscessus complex, and 31 Cases fulfilled the 2007 American Thoracic Society criteria for NTM infection (ATS+ Cases). Cases and ATS+ Cases were more likely to have low body mass index and colonization with Aspergillus fumigatus. Azithromycin was associated with a two-fold reduction in NTM isolates. Only one M. avium complex isolate had acquired macrolide resistance. These data suggest that azithromycin is a primary prophylaxis for NTM in...Continue Reading

References

Oct 29, 1994·BMJ : British Medical Journal·J M Bland, D G Altman
Apr 1, 1997·The Pediatric Infectious Disease Journal·B FaurouxH Vu Thien
Oct 2, 2003·JAMA : the Journal of the American Medical Association·Lisa SaimanUNKNOWN Macrolide Study Group
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
Jul 22, 2008·The Journal of Pediatrics·Philip M FarrellUNKNOWN Cystic Fibrosis Foundation
Oct 23, 2009·Journal of Clinical Microbiology·Anne-Laure RouxUNKNOWN Jean-Louis Herrmann for the OMA Group
Jan 15, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Charles R EstherPeadar G Noone
May 6, 2010·JAMA : the Journal of the American Medical Association·Lisa SaimanUNKNOWN AZ0004 Azithromycin Study Group
Aug 2, 2011·The Journal of Clinical Investigation·Maurizio RennaR Andres Floto
Jan 17, 2012·American Journal of Respiratory and Critical Care Medicine·Moira L AitkenRichard J Wallace
Feb 22, 2012·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Maarten VerregghenCornelis K van der Ent
Sep 1, 2012·The European Respiratory Journal·Emilie CatherinotUNKNOWN OMA group

❮ Previous
Next ❯

Citations

May 24, 2015·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Clair L PreeceJohn D Perry
May 14, 2016·Pediatric Pulmonology·Adrienne P Savant, Susanna A McColley
Jan 31, 2017·Pediatric Pulmonology·Jennifer M BousoOkan Elidemir
Jun 28, 2016·Therapeutic Advances in Chronic Disease·Claire Edmondson, Jane C Davies
Feb 24, 2018·Annals of the American Thoracic Society·Jonathan D CogenMargaret Rosenfeld
Jun 12, 2016·The European Respiratory Journal·Stefano AlibertiUNKNOWN EMBARC Study Group
May 13, 2017·The European Respiratory Journal·Laura J SherrardScott C Bell
Aug 4, 2020·Expert Opinion on Investigational Drugs·Ranjani SomayajiScott C Bell
Dec 31, 2016·Current Treatment Options in Infectious Diseases·Kate SkolnikBradley S Quon
Aug 15, 2020·Frontiers in Cellular and Infection Microbiology·Alexander J CurrieAdilia Warris
Jul 17, 2018·American Journal of Respiratory and Critical Care Medicine·André Schultz, Peter D Sly
Nov 18, 2020·Der Internist·F C RingshausenA-M Dittrich
Jan 12, 2021·The Pediatric Infectious Disease Journal·Didier HoNathalie Coolen-Allou
Dec 12, 2020·The European Respiratory Journal·Jonathan L GillanRobert D Gray

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Ophir Bar-OnHannah Blau
Annals of Clinical Microbiology and Antimicrobials
Dilek SatanaZayre Erturan
Seminars in Respiratory and Critical Care Medicine
In Kwon Park, Kenneth N Olivier
© 2022 Meta ULC. All rights reserved